A single MRI scan could soon tell doctors not just where a tumour is, but whether it will kill the patient within five years. Today, imaging often finds suspicious lesions without revealing whether they are cancerous or, if they are, how aggressive they are. A patient might hear that 50% of people with a similar pattern survive five years, but no one can say which half they fall into. This uncertainty forces many into unnecessary biopsies, surgeries, or toxic treatments. The centre aims to close that gap by combining advanced magnetic resonance technology with a detailed understanding of each tumour’s cellular and molecular environment. If successful, the approach could transform cancer care into a three-step process: find the target precisely, verify its true threat, then destroy it with pinpoint accuracy. The team already has a strong track record with prostate cancer therapies and plans to extend the same strategy to lung and gastrointestinal cancers. By co-locating engineers, surgeons, and imaging scientists in a dedicated translational facility at University College London, the centre aims to speed new technologies from the lab bench directly into the clinic.
View original technical description
Our vision is to revolutionise diagnosis, risk stratification and therapy for people with cancer based on innovations in magnetic resonance (MR) technology. The new system of care will be based on developing a strategy of optimized 'target generation', specific 'target verification' and precise 'target destruction' We use imaging to find out where cancer lies within the body. We call the process of taking an image to find a lesion 'target generation'. Whilst imaging helps to find disease we don't always know whether a lesion on an image is cancer or whether it is benign. Also, if a lesion is cancer we don't often know what that means for the individual patient. By way of explanation, we may know that a particular distribution of cancer spread within the body confers a poorer outcome for a group of patients e.g. a 50% of patients survive after 5-years; however, we often can't tell whether an individual patient will fall into the 50% that survive. Understanding the nature of a lesion detected on imaging and how this impacts on treatment choices and overall treatment outcome is termed 'target verification'. Our proposal seeks to establish a platform to allow new methods and advances we have been making in pre-clinical 'target generation' to be robustly and rapidly developed for clinical use. It also seeks to develop the best imaging technologies and combine these with an understanding of the cellular and molecular environment of cancers in order to significantly improve 'target verification'. The third aspect to our proposal is the development of new technologies to deliver precise treatment to individual cancer sites. We term this 'target destruction'. A range of technologies exist and we aim to provide the environment where the best and most promising of these can be easily translated from conception of idea all the way to clinical application. We have a strong track record in this area with therapies for prostate cancer and we seek to extend this to other cancer sites, initially lung and gastrointestinal cancers. Our proposal brings together a group of scientist with complementary skills in imaging, surgery and engineering in one location through establishing a dedicated Centre for Image Guided Therapy within University College London. Within this we seek to establish a translational imaging facility, which will reflect the type of imaging available within the clinical environment, and will also allow scientists access to the cutting-edge equipment to enable them to develop technological advances rapidly and robustly to a stage that they can be applied for patient benefit.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know